Offer, the biggest ever in the healthcare sector, values Allergan shares at $363.63 each

Merger will create world’s largest drugmaker and renew focus on Ireland’s role in tax inversion

Cantillon: Pfizer/Allergan deal the biggest of any sort yet attempted in pharma/medtech sector

CEO warns that any attempt to block a takeover by Pfizer would be a “short-sighted intervention”

No one questioning wisdom of approach or ability of companies to do a deal

Takeover could offer tax advantages given that Allergan is based in Dublin

Sales fell 2 per cent, hurt by generic competition and expiration of a deal with Amgen

Acquisition could allow the US drugmaker to move overseas and reduce taxes

British firm says US company had failed to make a compelling case

Plans to create world’s largest drug company in doubt as Pfizer offer fails to meet approval

This week: Straight-talk coins, ‘monetary morphine’ and stock ticker symbols with a difference

MPs told new entity would deliver much better outcomes for range of diseases

Westminster not happy with Ian Reid’s pledges on takeover of AstraZeneca

Chief executive Ian Read faces hostile questions over his proposed $106 billion play for UK firm

US firm says commitments to Britain are legally binding

Group is not known for being backwards when it comes to rationalisation

Pharma company’s record of cutting jobs after mergers has provoked a political backlash

US pharma giant reports first quarter sales of $730 million, below analyst estimates

US pharma giant is currently in a $100 million battle for Britain’s AstraZeneca

Chief executive Ian Read arrives in London for talks with government ministers